G. Kurteva

1.6k total citations · 1 hit paper
26 papers, 1.0k citations indexed

About

G. Kurteva is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, G. Kurteva has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in G. Kurteva's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (7 papers) and Gastric Cancer Management and Outcomes (7 papers). G. Kurteva is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (7 papers) and Gastric Cancer Management and Outcomes (7 papers). G. Kurteva collaborates with scholars based in United States, Hungary and Germany. G. Kurteva's co-authors include Pamela Salman, Markus Moehler, Yoon‐Koo Kang, Helena Melezínková, Florian Lordick, G. Bodoky, Constantin Volovăț, Vladimir Moiseyenko, Joon Oh Park and В. А. Горбунова and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

G. Kurteva

21 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations Florian Lordick, Yoon‐Koo Kang et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Kurteva United States	10	686	678	254	199	180	26	1.0k
Mariko Ogura Japan	15	694 1.0×	589 0.9×	254 1.0×	142 0.7×	166 0.9×	112	1.1k
Akitaka Makiyama Japan	17	715 1.0×	412 0.6×	154 0.6×	109 0.5×	193 1.1×	116	994
M Starnawski Austria	3	466 0.7×	660 1.0×	271 1.1×	268 1.3×	195 1.1×	5	862
Helena Melezínková United States	7	623 0.9×	624 0.9×	266 1.0×	193 1.0×	192 1.1×	9	1.0k
Guanghai Dai China	13	359 0.5×	354 0.5×	183 0.7×	125 0.6×	168 0.9×	34	670
Vanessa Tassell United States	13	417 0.6×	654 1.0×	127 0.5×	298 1.5×	164 0.9×	25	877
Takeo Kosaka Japan	15	219 0.3×	420 0.6×	322 1.3×	208 1.0×	95 0.5×	85	769
Yanzhi Hsu United States	16	340 0.5×	429 0.6×	192 0.8×	199 1.0×	108 0.6×	42	891
Katrina S. Pedersen United States	15	661 1.0×	220 0.3×	293 1.2×	84 0.4×	202 1.1×	73	970
Akira Ooki Japan	20	617 0.9×	456 0.7×	331 1.3×	97 0.5×	595 3.3×	98	1.4k

Countries citing papers authored by G. Kurteva

Since Specialization

Citations

This map shows the geographic impact of G. Kurteva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Kurteva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Kurteva more than expected).

Fields of papers citing papers by G. Kurteva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Kurteva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Kurteva. The network helps show where G. Kurteva may publish in the future.

Co-authorship network of co-authors of G. Kurteva

This figure shows the co-authorship network connecting the top 25 collaborators of G. Kurteva. A scholar is included among the top collaborators of G. Kurteva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Kurteva. G. Kurteva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnston, Stephen, Roberto Hegg, Seock‐Ah Im, et al.. (2020). Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. Journal of Clinical Oncology. 39(1). 79–89. 82 indexed citations

Kurteva, G., et al.. (2019). Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. European Journal of Pharmaceutical Sciences. 139. 105041–105041. 5 indexed citations

Glimelius, Bengt, Nebojša Manojlović, Per Pfeiffer, et al.. (2017). Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ^® ): a placebo-controlled randomised phase II study (PLIANT). Acta Oncologica. 57(3). 393–402. 63 indexed citations

Pintér, Tamás, Zandra Klippel, Alvydas Česas, et al.. (2016). A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clinical Colorectal Cancer. 16(2). 103–114.e3. 21 indexed citations

Kurteva, G., et al.. (2015). Identifying the Genetic Landscape of Squamous Cell Carcinoma (SCC) and Adenosquamous Carcinoma (ASC) of the Lung Using Next-Generation Sequencing (NGS). Annals of Oncology. 26. i1–i1. 1 indexed citations

Motzer, Robert J., Anna Alyasova, А. А. Карпенко, et al.. (2015). Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Annals of Oncology. 27(3). 441–448. 33 indexed citations

Muro, Kei, G. Bodoky, Alvydas Česas, et al.. (2015). RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis.. Journal of Clinical Oncology. 33(3_suppl). 11–11. 5 indexed citations

Alekseev, B. Yа., Lingwei Yang, Anna Alyasova, et al.. (2015). 2620 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Pooled anti-VEGF cohort subanalysis. European Journal of Cancer. 51. S518–S519. 1 indexed citations

Vazharova, Radoslava, et al.. (2015). TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer. memo - Magazine of European Medical Oncology. 9(1). 30–38. 3 indexed citations

10.

Wilke, H., P. Clingan, G. Kurteva, et al.. (2014). Rainbow: A Global, Phase 3, Double-Blind Study of Ramucirumab Plus Paclitaxel Versus Placebo Plus Paclitaxel in the Treatment of Gastric Cancer Following Disease Progression: Western Population Subgroup. Annals of Oncology. 25. ii106–ii106. 5 indexed citations

11.

Lordick, Florian, Yoon‐Koo Kang, Hyun Cheol Chung, et al.. (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. The Lancet Oncology. 14(6). 490–499. 621 indexed citations breakdown →

12.

Abella, Steve, Alvydas Česas, Adina Croitoru, et al.. (2013). Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology. 31(4_suppl). LBA445–LBA445. 4 indexed citations

13.

Pintér, Tamás, Esteban Abella, Alvydas Česas, et al.. (2013). Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology. 31(15_suppl). 3575–3575. 4 indexed citations

14.

Hoff, Paulo M., Andreas Hochhaus, Bernhard C. Pestalozzi, et al.. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology. 30(29). 3596–3603. 112 indexed citations

15.

Modest, Dominik Paul, Thomas Brodowicz, Sebastian Stintzing, et al.. (2012). Impact of the Specific Mutation in <b><i>KRAS</i></b> Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials. Oncology. 83(5). 241–247. 22 indexed citations

16.

Lordick, Florian, G. Bodoky, G. Kurteva, et al.. (2012). Cetuximab in Combination with Capecitabine and Cisplatin as First-Line Treatment in Advanced Gastric Cancer: Randomized Controlled Phase III Expand Study. Annals of Oncology. 23. ixe11–ixe11. 9 indexed citations

17.

Kurteva, G., et al.. (2012). Different chemotherapy schedules in metastatic colorectal cancer: a response and survival analysis.. PubMed. 7(2). 121–5.

18.

Kurteva, G., et al.. (2010). Imatinib mesylate in the management of gastrointestinal stromal tumours (GIST). memo - Magazine of European Medical Oncology. 3(2). 49–52.

19.

Ciuleanu, Tudor–Eliade, G. Kurteva, Janja Ocvirk, et al.. (2008). A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 26(15_suppl). 4032–4032. 9 indexed citations

20.

Ciuleanu, Tudor–Eliade, Werner Scheithauer, G. Kurteva, et al.. (2007). 3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer. European Journal of Cancer Supplements. 5(4). 249–249.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact